X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1631) 1631
Book Chapter (33) 33
Newspaper Article (5) 5
Magazine Article (3) 3
Conference Proceeding (1) 1
Newsletter (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1293) 1293
life sciences & biomedicine (1242) 1242
humans (1089) 1089
diabetes mellitus, type 2 - drug therapy (877) 877
type 2 diabetes (739) 739
diabetes (686) 686
dipeptidyl-peptidase iv inhibitors - therapeutic use (639) 639
hypoglycemic agents - therapeutic use (530) 530
endocrinology & metabolism (517) 517
male (476) 476
diabetes mellitus (387) 387
female (376) 376
pharmacology & pharmacy (358) 358
animals (334) 334
glucose (328) 328
middle aged (309) 309
treatment outcome (287) 287
aged (285) 285
dipeptidyl-peptidase iv inhibitors - adverse effects (281) 281
hypoglycemic agents (273) 273
dipeptidyl-peptidase iv inhibitors - pharmacology (266) 266
risk factors (252) 252
drug therapy (248) 248
type 2 diabetes mellitus (248) 248
hypoglycemic agents - adverse effects (247) 247
diabetes mellitus, type 2 - blood (241) 241
clinical trials (226) 226
cardiovascular system & cardiology (223) 223
internal medicine (213) 213
insulin (209) 209
peptidase (209) 209
analysis (203) 203
care and treatment (200) 200
cardiac & cardiovascular systems (199) 199
diabetes mellitus, type 2 - complications (198) 198
medicine & public health (198) 198
heart failure (179) 179
diabetes therapy (177) 177
blood glucose - drug effects (176) 176
glucagon (174) 174
hypoglycemic agents - pharmacology (174) 174
uracil - analogs & derivatives (173) 173
research (168) 168
cardiovascular disease (167) 167
dextrose (167) 167
dpp-4 inhibitors (166) 166
adult (164) 164
studies (164) 164
dpp-4 inhibitor (163) 163
patients (159) 159
hypoglycemic agents - administration & dosage (158) 158
dipeptidyl peptidase 4 - metabolism (157) 157
drug therapy, combination (156) 156
cardiovascular diseases (155) 155
blood glucose - metabolism (152) 152
alogliptin (149) 149
dipeptidyl-peptidase iv inhibitors - administration & dosage (149) 149
metformin (149) 149
mortality (148) 148
adamantane - analogs & derivatives (142) 142
sitagliptin (142) 142
hypoglycemia (140) 140
inhibitors (139) 139
linagliptin (139) 139
review (134) 134
health aspects (129) 129
peptides (128) 128
randomized controlled trials as topic (124) 124
general & internal medicine (121) 121
medicine, general & internal (117) 117
dipeptidyl peptidase-4 inhibitor (116) 116
dipeptidyl peptidase-4 inhibitors (115) 115
medical research (115) 115
insulin resistance (112) 112
glycated hemoglobin a - metabolism (110) 110
cardiology (109) 109
piperidines - therapeutic use (109) 109
diabetes mellitus, type 2 - metabolism (108) 108
endocrinology (106) 106
uracil - therapeutic use (106) 106
vildagliptin (104) 104
glycosylated hemoglobin (103) 103
abridged index medicus (102) 102
meta-analysis (102) 102
drugs (100) 100
hyperglycemia (99) 99
metformin - therapeutic use (99) 99
saxagliptin (99) 99
cardiovascular diseases - prevention & control (98) 98
dosage and administration (96) 96
heart diseases (94) 94
double-blind method (93) 93
time factors (93) 93
health risk assessment (92) 92
incretins - therapeutic use (92) 92
medicine (91) 91
mice (90) 90
adamantane - therapeutic use (89) 89
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (88) 88
diabetics (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1652) 1652
Japanese (15) 15
Russian (7) 7
French (5) 5
German (4) 4
Chinese (2) 2
Korean (2) 2
Czech (1) 1
Hungarian (1) 1
Italian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes care, ISSN 1935-5548, 01/2016, Volume 39, Issue 1, pp. 139 - 148
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of 18 months... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 12/2014, Volume 16, Issue 12, pp. 1239 - 1246
Aims To evaluate the long‐term durability of the efficacy of alogliptin compared with glipizide in combination with metformin in people with type 2 diabetes inadequately controlled on stable‐dose metformin... 
antidiabetic drug | randomised trial | diabetes mellitus | glycaemic control | DPP‐IV inhibitor | incretin therapy | Incretin therapy | Antidiabetic drug | Diabetes mellitus | Randomised trial | Glycaemic control | DPP-IV inhibitor | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Metformin - therapeutic use | Glipizide - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glipizide - adverse effects | Glycated Hemoglobin A - drug effects | Male | Glipizide - therapeutic use | Metformin - adverse effects | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Uracil - administration & dosage | Hypoglycemic Agents - administration & dosage | Adult | Female | Metformin - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Uracil - therapeutic use | Treatment Outcome | Pancreatitis - chemically induced | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Aged | Cardiovascular Diseases - chemically induced | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Uracil - analogs & derivatives | Type 2 diabetes | Glucose metabolism | Pancreatitis | Glipizide | Glucose | Comparative analysis | Dextrose | Patients | Medical treatment | Diabetes | Index Medicus
Journal Article
Journal Article
American Journal of Physiology - Renal Physiology, ISSN 0363-6127, 10/2012, Volume 303, Issue 7, pp. F963 - F971
Journal Article
Drug design, development and therapy, ISSN 1177-8881, 09/2013, Volume 7, pp. 989 - 1001
...' (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety... 
Type 2 diabetes | DPP-4 inhibitors | Alogliptin | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Hypoglycemic Agents - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Uracil - therapeutic use | Clinical Trials as Topic | Molecular Targeted Therapy | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Hypoglycemic Agents - pharmacology | Uracil - pharmacology | Animals | Diabetes Mellitus, Type 2 - physiopathology | Drug Interactions | Uracil - adverse effects | Piperidines - pharmacology | Piperidines - therapeutic use | Piperidines - adverse effects | Adult | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Uracil - analogs & derivatives | Physiological aspects | Research | Metabolites | Diabetes therapy | Heart | Therapy | Glucagon | Liver | Selectivity | Hormones | Congestive heart failure | Plasma proteins | Older people | Hemoglobin | Pancreas | Glibenclamide | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Excretion | Liver diseases | Peptidase | Pioglitazone | Diabetes mellitus | Bioavailability | Metabolism | Insulin | Patients | Inhibitors | Renal failure | Diabetes | Metformin | Geriatrics | Index Medicus
Journal Article
Journal Article